What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2447.png

LEQVIO® Is the first and only LDL-C-lowering therapy that is
dosed twice a year.1*

*LEQVIO® is dosed initially, again at 3 months, and then once every 6 months.1

Group 2452.png
Group 2453.png

†LEQVIO® should appear clear, pale yellow to colorless.1 This color variation is normal and has no impact on the overall quality of LEQVIO®.
 

  •  Each prefilled syringe contains 284 mg LEQVIO® in 1.5 ml of solution1
  • Do not store above 25 °C. Do not freeze2-6
  • LEQVIO® is administered in the abdomen. Alternative injection sites include the upper arm or thigh1

 

Missed doses

 

  • If a planned dose is missed by less than 3 months, LEQVIO® should be administered and dosing continued according to the patient's original schedule1
  • If a planned dose is missed by more than 3 months, a new dosing schedule should be started-LEQVIO® should be administered initially, again at 3 months, followed by once every 6 months1

 

Special precautions for disposal1

 

LEQVIO® should be inspected visually prior to administration. The solution should appear clear, pale yellow to colorless. If the solution contains visible particulate matter, the solution should not be used.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

LEQVIO® NSS -  UAE

PDF
View

References

  1. LEQVIO® . Core Data Sheet. Novartis Europharma limited.

  2. Data on file. ORION-10 (MDCO-PCS-17-04) Clinical Study Report. The Medicines Company; 2019. "to be provided if requested."

  3. Data on file. ORION-9 (MDC-PCS-17-03) Clinical Study Report. The Medicines Company; 2019.
"to be provided if requested."

  4. Data on file. ORION-11 (MDCO-PCS-17-08) Clinical Study Report. The Medicines Company; 2019."to be provided if requested."

  5. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of
inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020,382(16):1507-1519.
doi:10.1056/NEJMoa1912387


  6. Raal FJ, Kallend D, Ray KK, et al; ORION-9 Investigators. Inclisiran for the treatment of heterozygous
familial hypercholesterolemia. N Engel K Med. 2020;1:1-11. doi:10.1056/NEJMoa1913805